# World Journal of *Diabetes*

World J Diabetes 2024 March 15; 15(3): 308-574





Published by Baishideng Publishing Group Inc

World Journal of Diabetes

### Monthly Volume 15 Number 3 March 15, 2024

### **EDITORIAL**

308 Unlocking new potential of clinical diagnosis with artificial intelligence: Finding new patterns of clinical and lab data

Dabla PK

311 Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: The pathobiology and therapeutic implications

Blaibel D, Fernandez CJ, Pappachan JM

- 318 Periodontitis: An often-neglected complication of diabetes Kudiyirickal MG, Pappachan JM
- 326 Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards

Horowitz M, Cai L, Islam MS

### **REVIEW**

331 Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus

Alqifari SF, Alkomi O, Esmail A, Alkhawami K, Yousri S, Muqresh MA, Alharbi N, Khojah AA, Aljabri A, Allahham A, Prabahar K, Alshareef H, Aldhaeefi M, Alrasheed T, Alrabiah A, AlBishi LA

348 Association of autoimmune thyroid disease with type 1 diabetes mellitus and its ultrasonic diagnosis and management

Wang J, Wan K, Chang X, Mao RF

- 361 Metabolic disorders in prediabetes: From mechanisms to therapeutic management Ping WX, Hu S, Su JQ, Ouyang SY
- 378 Epigenetic modifications of placenta in women with gestational diabetes mellitus and their offspring Yi Y, Wang T, Xu W, Zhang SH

### **MINIREVIEWS**

392 Roles of fibroblast growth factors in the treatment of diabetes

Zhang CY, Yang M

### **ORIGINAL ARTICLE**

### **Case Control Study**

403 Associations between Geriatric Nutrition Risk Index, bone mineral density and body composition in type 2 diabetes patients

Zhu XX, Yao KF, Huang HY, Wang LH



Monthly Volume 15 Number 3 March 15, 2024

418 Predictive value of angiopoietin-like protein 8 in metabolic dysfunction-associated fatty liver disease and its progression: A case-control study

Gan LL, Xia C, Zhu X, Gao Y, Wu WC, Li Q, Li L, Dai Z, Yan YM

### **Retrospective Study**

429 Myosteatosis is associated with coronary artery calcification in patients with type 2 diabetes

Liu FP, Guo MJ, Yang Q, Li YY, Wang YG, Zhang M

440 Adherence to Advisory Committee on Immunization Practices in diabetes mellitus patients in Saudi Arabia: A multicenter retrospective study

Alqifari SF, Esmail AK, Alarifi DM, Alsuliman GY, Alhati MM, Mutlaq MR, Aldhaeefi M, Alshuaibi SA, Amirthalingam P, Abdallah A, Wasel AS, Hamad HR, Alamin S, Atia TH, Alqahtani T

### **Observational Study**

455 Evaluation of hybrid closed-loop insulin delivery system in type 1 diabetes in real-world clinical practice: One-year observational study

Eldib A, Dhaver S, Kibaa K, Atakov-Castillo A, Salah T, Al-Badri M, Khater A, McCarragher R, Elenani O, Toschi E, Hamdy O

463 Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience

Islam L, Jose D, Alkhalifah M, Blaibel D, Chandrabalan V, Pappachan JM

### **Clinical and Translational Research**

475 Dietary fiber intake and its association with diabetic kidney disease in American adults with diabetes: A cross-sectional study

Jia XH, Wang SY, Sun AQ

### **Basic Study**

488 MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4

Wu QS, Zheng DN, Ji C, Qian H, Jin J, He Q

502 Jianpi Gushen Huayu decoction ameliorated diabetic nephropathy through modulating metabolites in kidney, and inhibiting TLR4/NF-KB/NLRP3 and JNK/P38 pathways

Ma ZA, Wang LX, Zhang H, Li HZ, Dong L, Wang QH, Wang YS, Pan BC, Zhang SF, Cui HT, Lv SQ

- 519 Diabetes and high-glucose could upregulate the expression of receptor for activated C kinase 1 in retina Tan J, Xiao A, Yang L, Tao YL, Shao Y, Zhou Q
- 530 Potential application of Nardostachyos Radix et Rhizoma-Rhubarb for the treatment of diabetic kidney disease based on network pharmacology and cell culture experimental verification

Che MY, Yuan L, Min J, Xu DJ, Lu DD, Liu WJ, Wang KL, Wang YY, Nan Y

### SYSTEMATIC REVIEWS

552 KCNQ1 rs2237895 gene polymorphism increases susceptibility to type 2 diabetes mellitus in Asian populations

Li DX, Yin LP, Song YO, Shao NN, Zhu H, He CS, Sun JJ



### Monthly Volume 15 Number 3 March 15, 2024

### **LETTER TO THE EDITOR**

- Chiglitazar and Thiazolidinedione in patients with type 2 diabetes: Which is better? 565 Reddy KS, Gaur A, Varatharajan S, Morya AK
- 568 Effects of vitamin family members on insulin resistance and diabetes complications Chen HJ, Wang M, Zou DM, Liang GY, Yang SY
- 572 Regulatory role of peroxynitrite in advanced glycation end products mediated diabetic cardiovascular complications

Bala A



Monthly Volume 15 Number 3 March 15, 2024

### **ABOUT COVER**

Editorial Board Member of World Journal of Diabetes, Jun-Ling Shi, PhD, Professor, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, Shaanxi Province, China. sjlshi2004@nwpu.edu.cn

### **AIMS AND SCOPE**

The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WID mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

### **INDEXING/ABSTRACTING**

The WID is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJD as 4.2; IF without journal self cites: 4.1; 5-year IF: 4.5; Journal Citation Indicator: 0.69; Ranking: 51 among 145 journals in endocrinology and metabolism; and Quartile category: Q2.

### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Editorial Office Director: Ju-Ru Fan.

NAME OF JOURNAL World Journal of Diabetes	INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1948-9358 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
June 15, 2010	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Lu Cai, Md. Shahidul Islam, Michael Horowitz	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-9358/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
March 15, 2024	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



WJD

# World Journal of Diabetes

Submit a Manuscript: https://www.f6publishing.com

World J Diabetes 2024 March 15; 15(3): 552-564

DOI: 10.4239/wjd.v15.i3.552

ISSN 1948-9358 (online)

SYSTEMATIC REVIEWS

# KCNQ1 rs2237895 gene polymorphism increases susceptibility to type 2 diabetes mellitus in Asian populations

Dong-Xu Li, Li-Ping Yin, Yu-Qi Song, Nan-Nan Shao, Huan Zhu, Chen-Sen He, Jiang-Jie Sun

Specialty type: Endocrinology and metabolism

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

### Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Beg MMA, Kyrgyzstan; Horowitz M, Australia

Received: September 25, 2023 Peer-review started: September 25, 2023

First decision: December 6, 2023 Revised: December 13, 2023 Accepted: February 2, 2024 Article in press: February 2, 2024 Published online: March 15, 2024



Dong-Xu Li, Yu-Qi Song, Huan Zhu, First Clinical Medical College, Anhui Medical University, Hefei 230032, Anhui Province, China

Li-Ping Yin, Chen-Sen He, School of Mental Health and Psychological Sciences, Anhui Medical University, Hefei 230032, Anhui Province, China

Nan-Nan Shao, School of Clinical Medicine, Anhui Medical University, Hefei 230031, Anhui Province, China

Jiang-Jie Sun, School of Health Care Management, Anhui Medical University, Hefei 230032, Anhui Province, China

Corresponding author: Jiang-Jie Sun, PhD, Professor, School of Health Care Management, Anhui Medical University, No. 81 Meishan Road, Hefei 230032, Anhui Province, China. sunjiangjie@ahmu.edu.cn

### Abstract

### BACKGROUND

The association of single nucleotide polymorphism of *KCNQ1* gene rs2237895 with type 2 diabetes mellitus (T2DM) is currently controversial. It is unknown whether this association can be gene realized across different populations.

### AIM

To determine the association of KCNQ1 rs2237895 with T2DM and provide reliable evidence for genetic susceptibility to T2DM.

### **METHODS**

We searched PubMed, Embase, Web of Science, Cochrane Library, Medline, Baidu Academic, China National Knowledge Infrastructure, China Biomedical Literature Database, and Wanfang to investigate the association between KCNQ1 gene rs2237895 and the risk of T2DM up to January 12, 2022. Review Manager 5.4 was used to analyze the association of the KCNQ1 gene rs2237895 polymorphism with T2DM and to evaluate the publication bias of the selected literature.

### RESULTS

Twelve case-control studies (including 11273 cases and 11654 controls) met our inclusion criteria. In the full population, allelic model [odds ratio (OR): 1.19; 95% confidence interval (95%CI): 1.09–1.29; *P* < 0.0001], recessive model (OR: 1.20; 95%CI: 1.11-1.29; P < 0.0001), dominant model (OR: 1.27. 95%CI: 1.14-1.42; P <



WJD | https://www.wjgnet.com

0.0001), and codominant model (OR: 1.36; 95%CI: 1.15–1.60; P = 0.0003) (OR: 1.22; 95%CI: 1.10–1.36; P = 0.0002) indicated that the *KCNQ1* gene rs2237895 polymorphism was significantly correlated with susceptibility to T2DM. In stratified analysis, this association was confirmed in Asian populations: allelic model (OR: 1.25; 95%CI: 1.13–1.37; P < 0.0001), recessive model (OR: 1.29; 95%CI: 1.11–1.49; P = 0.0007), dominant model (OR: 1.35; 95%CI: 1.20–1.52; P < 0.0001), codominant model (OR: 1.49; 95%CI: 1.22–1.81; P < 0.0001) (OR: 1.26; 95%CI: 1.16–1.36; P < 0.0001). In non-Asian populations, this association was not significant: Allelic model (OR: 1.06, 95%CI: 0.98–1.14; P = 0.12), recessive model (OR: 1.04; 95%CI: 0.75–1.42; P = 0.83), dominant model (OR: 1.06; 95%CI: 0.98–1.15; P = 0.15), codominant model (OR: 1.08; 95%CI: 0.82–1.42; P = 0.60. OR: 1.15; 95%CI: 0.95–1.39; P = 0.14).

### CONCLUSION

*KCNQ1* gene rs2237895 was significantly associated with susceptibility to T2DM in an Asian population. Carriers of the C allele had a higher risk of T2DM. This association was not significant in non-Asian populations.

Key Words: Type 2 diabetes mellitus; KCNQ1; rs2237895; Single nucleotide polymorphism; Asian populations

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In Asian populations, the rs2237895 polymorphism in the *KCNQ1* gene was significantly associated with susceptibility to type 2 diabetes mellitus (T2DM), and C allele carriers had an increased risk of developing T2DM. The CC and AC genotypes of *KCNQ1* rs2237895 significantly increased the susceptibility to T2DM. In non-Asian populations, this association was not significant.

Citation: Li DX, Yin LP, Song YQ, Shao NN, Zhu H, He CS, Sun JJ. *KCNQ1* rs2237895 gene polymorphism increases susceptibility to type 2 diabetes mellitus in Asian populations. *World J Diabetes* 2024; 15(3): 552-564 URL: https://www.wjgnet.com/1948-9358/full/v15/i3/552.htm DOI: https://dx.doi.org/10.4239/wjd.v15.i3.552

### INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a common multifactorial, metabolic disease whose pathogenesis is influenced by a combination of genetic and environmental factors. The rise and large-scale application of genome-wide association studies have contributed to the understanding of genetic factors related to T2DM. T2DM remains a health problem that plagues the world to this day. As of January 4, 2021, the number of people with diabetes worldwide had reached 537 million. Even more alarmingly, this number is expected to increase to 643 million by 2030. The various expenditures due to diabetes have exceeded \$966 billion, and this figure has grown at an annual rate of 63% since 2006[1]. The etiology of T2DM is complex and has not yet been fully elucidated. T2DM is characterized by defective insulin secretion and reduced sensitivity, leading to chronic hyperglycemia and severe metabolic dysfunction in patients[2,3]. Hyperglycemia affects the physiological function of several tissues and organs in the body, among which the most common are neuropathy and vascular complications[1].

Studies have not provided an accurate description of the etiology of T2DM, and a genome-wide scan of Japanese by Nawata *et al*[4] showed that *KCNQ1* is a susceptibility gene for T2DM in Japan. In addition, genes such as *ADRA2A*, *KCNJ11 and CDKAL1* may be associated with the development of T2DM[4,5]. *KCNQ1* is a potassium channel subunit that is mainly found in adipose and pancreatic tissues. It was found that *KCNQ1* affects the process of islet  $\beta$ -cell depolarization by regulating potassium channel currents, thereby limiting insulin secretion from pancreatic  $\beta$ -cells and leading to the development of T2DM[6].

Previous studies have found that C allele carriers of the *KCNQ1* gene rs2237895 may have an increased risk of developing T2DM[7]. rs2237895 is present in three genotypes in the population, AA, AC and CC. The A gene is wild type and the C gene is mutant, and their gene frequencies in the population are approximately 66% and 34%[8]. A study by Cui *et al*[7] in Kazakhs living in China showed that rs2237895 single nucleotide polymorphism (SNP) of *KCNQ1* gene was not significantly associated with T2DM. A study by Afshardoost *et al*[9] on Iranians also showed no significant association between rs2237895 and T2DM; while in a study by Khan *et al*[10] on Indians, they confirmed a significant association between the SNP of rs2237895 and T2DM. Previously, a similar study has been conducted by Sun *et al*[11], but we consider that their inclusion criteria were more lenient and the strength of the proof may be weakened. Meanwhile, their work was > 10 years old and many new studies have been published during this period and that meta-analysis is in urgent need of updating. To address the above issues, we performed the present meta-analysis.

Zaishideng® WJD | https://www.wjgnet.com




Figure 1 Literature screening process.

### MATERIALS AND METHODS

### Literature search

The following nine electronic databases were searched: PubMed, Embase, Web of Science, Cochrane Library, Medline, Baidu Academic, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), and Wanfang Database, with the following search formulas: Subject (T2DM) and keywords (KCNQ1) and keywords (rs2237895). The last search date was January 12, 2022. Chinese and English literature on the association of the rs2237895 SNP in the KCNQ1 gene with T2DM was collected. The inclusion criteria for the articles were: (1) T2DM patients in the case group met the diagnostic criteria for diabetes published by WHO in 1999 or American Diabetes Association in 2010; (2) the type of experiment was a case-control study or a cohort study; (3) there was sufficient information in the text to describe the genotype and allele frequencies of the case and control groups; (4) the patients in the control group all met the Hardy-Weinberg genetic equilibrium model; (5) patients were randomly selected with no special restrictions on age, sex, or family history; and (6) for duplicate or data-identical literature, the one with the most complete information. Exclusion criteria were: (1) Incomplete study data; (2) literature reviews; (3) studies with gestational diabetes as an endpoint; and (4) exclusion of studies with familial diabetes as a basis.

### Data extraction

Two researchers independently performed literature screening and extraction of information based on the above criteria. A third researcher was required to discuss and agree on the results when difficult differences were encountered. For each article, we collected the basic information that needed to be used for Meta-analysis, and the literature screening process is shown in Figure 1.

### Statistical analysis

The data were processed using Review Manager 5.4. The strength of association between SNPs in the KCNQ1 gene rs2237895 and the risk of T2DM was assessed using the odds ratio (OR) and its corresponding 95% confidence interval (95%CI) as a criterion in the data statistics. The forest plots were used to show the OR and its 95%CI for each study. The



Zaishidene® WJD | https://www.wjgnet.com

Table 1 Characteristics of the include	d literature										
D-f	Etheria itu	N		Age (yr)		Case			Cont	rol	
Ref.	Ethnicity	Case	Control	Case	Control	AA	AC	CC	AA	AC	CC
Cui et al[7], 2016	Kazakh	100	100	51.21 ± 11.60	$49.85 \pm 12.41$	40	49	11	32	51	17
Khan <i>et al</i> [10], 2020	Indian	300	100	$40.33 \pm 9.76$	$35.29 \pm 7.96$	90	153	57	50	36	14
Liu et al[12], 2009	Chinese	1885	1994	$63.9\pm9.50$	$58.10\pm9.40$	790	886	209	942	883	169
Zhang[13], 2010	Chinese	100	97	$63.90\pm9.50$	$58.1 \pm 9.40$	25	36	39	43	34	20
Dai et al[14], 2012	Chinese	367	214	$49.13 \pm 10.79$	$47.55 \pm 10.93$	134	168	65	99	87	28
Li <i>et al</i> [ <b>15</b> ], 2020	Chinese	1194	1292	$52.49 \pm 12.10$	$52.70 \pm 10.52$	509	568	117	621	552	119
Hu <i>et al</i> [16], 2021	Chinese	277	279	$52.26 \pm 9.49$	$52.26 \pm 9.49$	121	123	33	145	113	21
Saif-Ali <i>et al</i> [17], 2011	Malaysian	300	230	$49.80 \pm 7.42$	$52.90\pm9.15$	123	147	30	120	96	14
Almawi <i>et al</i> [18], 2013	Arabs	995	1076	$58.6 \pm 13.40$	$57.30 \pm 10.40$	324	497	174	413	511	152
Al-Shammari et al[19], 2017	Arabs	320	516	$51.50\pm8.75$	$48.75\pm6.85$	122	150	58	202	223	91
van Vliet-Ostaptchouk et al[20], 2012	Dutch	4549	5182	$64.36 \pm 10.6$	$51.16\pm10.10$	1522	2158	869	1803	2516	863
Turki <i>et al</i> [ <mark>21</mark> ], 2012	Arabs	886	574	$61.20\pm9.70$	$52.00 \pm 11.9$	350	429	107	233	261	80

pooled results were directly observed on the forest plots. The difference was considered significant when the 95% CI did not include 1. Allelic model (C *vs* A), recessive model (CC *vs* AA + AC), dominant model (CC + AC *vs* AA) and codominant model (CC *vs* AA and AC *vs* AA) were used to assess the genetic effects of the genes. The significance level was set at P < 0.05. The random-effect model was used to calculate the effect size when the heterogeneity was  $l^2 > 50\%$ , and the fixed-effect model was used when  $l^2$  was < 50%. Publication bias was assessed by Egger's test and funnel plot. In the funnel plot, the dashed line perpendicular to the horizontal axis indicated the combined effect size. It suggested that the studies were without publication bias when the distribution of studies in the funnel plot was approximately symmetrical.

### RESULTS

According to the research strategy, 323 relevant papers were retrieved from the databases. Some duplicates were found and we removed them by Endnote software. We also screened the citations of the paper to ensure the comprehensiveness of the search. After a stepwise screening process, 12 eligible papers were finally included for meta-analysis, which included 11273 patients with T2DM and 11654 controls. Five of the datasets were from China[12-16], five from the rest of Asia[7,10,17-19], one from Europe[20], and one from Africa[21]. The basic information of the studies is shown in Table 1.

The 12 datasets that met the inclusion criteria were pooled for meta-analysis, and allelic, recessive, dominant, and codominant models were used to investigate the association of rs2237895 with T2DM. Since the study population was predominantly Asian, we performed stratified analysis of Asian and non-Asian populations (Figure 2 and Figure 3).

In the full population, allelic model (OR: 1.19; 95%CI: 1.09–1.29; P < 0.0001), recessive model (OR: 1.20; 95%CI: 1.11–1.29; P < 0.0001), dominant model (OR: 1.27. 95%CI: 1.14–1.42; P < 0.0001), and codominant model (OR: 1.36; 95%CI: 1.15–1.60; P = 0.0003. OR: 1.22; 95%CI: 1.10–1.36; P = 0.0002) all showed significant association between rs2237895 and T2DM. In the subgroup of the Asian population, allelic model (OR: 1.25; 95%CI: 1.13–1.37; P < 0.0001), recessive model (OR: 1.29; 95%CI: 1.11–1.49; P = 0.0007), dominant model (OR: 1.35; 95%CI: 1.20–1.52; P < 0.0001), and codominant model (OR: 1.49; 95%CI: 1.22–1.81; P < 0.0001). OR: 1.26; 95% CI: 1.16–1.36; P < 0.0001) also showed a significant association between rs2237895 and T2DM, which was consistent with the whole population. C allele carriers had an increased risk of developing T2DM. The CC and AC genotypes significantly increased the risk of T2DM compared to the AA genotype. However, in the non-Asian population subgroup, allelic model (OR: 1.06; 95%CI: 0.98–1.14; P = 0.12), recessive model (OR: 1.04; 95%CI: 0.75–1.42; P = 0.83), dominant model (OR: 1.06; 95%CI: 0.98–1.15; P = 0.15), and codominant model (OR: 1.08; 95%CI: 0.82–1.42; P = 0.60) (OR: 1.15; 95%CI: 0.95–1.39; P = 0.14) all showed no significant association between rs2237895 and T2DM.

The funnel plots showed no significant publication bias was found in the meta-analysis (Figure 4 and Figure 5). Egger's test showed no significant publication bias for the allelic model (t = 1.84, P = 0.095), recessive model (t = 0.48, P = 0.64), dominant model (t = 1.44, P = 0.18), and codominant model (t = 1.33, P = 0.21; t = 1.79, P = 0.10).

We performed a sensitivity analysis. After sequentially excluding one study in the allelic model, recessive model, dominant model, and codominant model, we calculated the pooled effect sizes for the remaining studies. By calculation, no qualitative change occurred between the pooled results of the remaining studies and the original results. Sensitivity analysis proved that the results of the meta-analysis were reliable.

Zaishidena® WJD https://www.wjgnet.com

### A

	T2DM	I	Contr	ol		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 959	%CI M-H, random, 95%CI
Amira Turki 2012	643	1772	421	1148	10.2%	0.98 [0.84, 1.15]	+
Fulan Hu 2021	189	554	155	558	6.4%	1.35 [1.04, 1.74]	
Jana V. van Vliet-Ostaptchouk 2012	3896	9098	4242	10364	14.7%	1.08 [1.02, 1.14]	•
L.J. Cui 2016	71	200	85	200	3.4%	0.74 [0.50, 1.11]	·
Li Zhang 2010	114	200	77	197	3.4%	2.07 [1.38, 3.08]	— <b>—</b>
Maha S. Al-Shammari 2017	266	660	405	1032	8.3%	1.05 [0.86, 1.28]	· +
Riyadh Saif-Ali 2011	207	600	124	460	6.0%	1.43 [1.09, 1.86]	<b>-</b>
Vasiuddin Khan 2020	264	600	64	200	4.4%	1.67 [1.19, 2.34]	
Wassim Y. Almawi 2013	845	1990	815	2152	11.7%	1.21 [1.07, 1.37]	-
Xing-Ping Dai 2012	298	734	143	428	6.5%	1.36 [1.06, 1.75]	
Y. Liu 2009	1304	3770	1221	3988	13.1%	1.20 [1.09, 1.32]	-
Yiping Li 2020	802	2388	790	2584	11.9%	1.15 [1.02, 1.29]	-
Total (95% CI)		22566		23311	100.0%	1.19 [1.09, 1.29]	•
Total events	8899		8542				
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 33	.54, df = 11	(P = 0.0	0004); I <sup>z</sup> :	= 67%			
Test for overall effect: Z = 4.09 (P < 0.							0.01 0.1 1 10 100 Favours [experimental] Favours [control]

### В

	T2DM		Contro			Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95%	CI M-H, fixed, 95%CI
Amira Turki 2012	107	886	80	574	6.7%	0.85 [0.62, 1.16]	
Fulan Hu 2021	33	277	21	279	1.5%	1.66 [0.94, 2.95]	
Jana V. van Vliet-Ostaptchouk 2012	869	4549	863	5182	51.4%	1.18 [1.07, 1.31]	
L.J. Cui 2016	11	100	17	100	1.2%	0.60 [0.27, 1.36]	
Li Zhang 2010	39	100	20	97	1.0%	2.46 [1.30, 4.65]	
Maha S. Al-Shammari 2017	58	320	91	516	4.5%	1.03 [0.72, 1.49]	
Riyadh Saif-Ali 2011	30	300	14	230	1.1%	1.71 [0.89, 3.31]	
Vasiuddin Khan 2020	57	300	14	100	1.3%	1.44 [0.76, 2.72]	
Wassim Y. Almawi 2013	174	995	152	1076	9.5%	1.29 [1.02, 1.63]	
Xing-Ping Dai 2012	65	367	28	214	2.3%	1.43 [0.89, 2.31]	
Y. Liu 2009	209	1885	169	1994	11.5%	1.35 [1.09, 1.67]	
Yiping Li 2020	117	1194	119	1292	8.1%	1.07 [0.82, 1.40]	
Total (95% CI)		11273		11654	<b>100.0</b> %	1.20 [1.11, 1.29]	◆
Total events	1769		1588				
Heterogeneity: Chi <sup>2</sup> = 18.51, df = 11	(P = 0.07);	l <sup>2</sup> = 41%	5				
Test for overall effect: Z = 4.82 (P < 0	0.00001)						0.2 0.5 1 2 5 Favours (experimental) Favours (control)

## С

	T2DM	1	Contro	ol		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95%C	CI M-H, random, 95%CI
Amira Turki 2012	536	886	341	574	10.2%	1.05 [0.84, 1.30]	
Fulan Hu 2021	156	277	134	279	6.7%	1.40 [1.00, 1.95]	
Jana V. van Vliet-Ostaptchouk 2012	3027	4549	3379	5182	15.0%	1.06 [0.98, 1.15]	
L.J. Cui 2016	60	100	68	100	3.0%	0.71 [0.40, 1.26]	
Li Zhang 2010	75	100	54	97	2.8%	2.39 [1.31, 4.37]	
Maha S. Al-Shammari 2017	208	320	314	516	7.8%	1.19 [0.89, 1.60]	
Riyadh Saif-Ali 2011	177	300	110	230	6.4%	1.57 [1.11, 2.22]	
Vasiuddin Khan 2020	210	300	50	100	4.3%	2.33 [1.47, 3.71]	<del></del>
Wassim Y. Almawi 2013	671	995	663	1076	11.5%	1.29 [1.08, 1.55]	_ <b>_</b>
Xing-Ping Dai 2012	233	367	115	214	6.5%	1.50 [1.06, 2.11]	
Y. Liu 2009	1095	1885	1052	1994	13.5%	1.24 [1.09, 1.41]	
Yiping Li 2020	685	1194	671	1292	12.3%	1.25 [1.06, 1.46]	
Total (95% CI)		11273		11654	100.0%	1.27 [1.14, 1.42]	◆
Total events	7133		6951				
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 31	.32, df = 11	I (P = 0.0	0010); I <sup>z</sup> =	65%		-	
Test for overall effect: Z = 4.21 (P < 0	.0001)						0.5 0.7 1 1.5 2 Favours [experimental] Favours [control]

Baisbideng® WJD | https://www.wjgnet.com

Study or subgroup	T2DM Events		Contr Events		l Weiahl	Odds ratio t M-H, random, 95%(	Odds ratio CI M-H, random, 95%CI
Amira Turki 2012	107	457	80	313	10.3%	0.89 [0.64, 1.24]	
Fulan Hu 2021	33	407	21				
				166	5.3%	1.88 [1.04, 3.42]	
Jana V. van Vliet-Ostaptchouk 2012	869	2391	863	2666	16.2%	1.19 [1.06, 1.34]	
L.J. Cui 2016	11	51	17	49	2.9%	0.52 [0.21, 1.26]	
Li Zhang 2010	39	64	20	63	4.0%	3.35 [1.62, 6.96]	
Maha S. Al-Shammari 2017	58	180	91	293	8.7%	1.06 [0.71, 1.57]	
Riyadh Saif-Ali 2011	30	153	14	134	4.4%	2.09 [1.06, 4.14]	
Vasiuddin Khan 2020	57	147	14	64	4.4%	2.26 [1.15, 4.46]	
Wassim Y. Almawi 2013	174	498	152	565	12.2%	1.46 [1.12, 1.90]	
Xing-Ping Dai 2012	65	199	28	127	6.5%	1.72 [1.03, 2.87]	
Y. Liu 2009	209	999	169	1111	13.3%	1.47 [1.18, 1.84]	
Yiping Li 2020	117	626	119	740	11.7%	1.20 [0.91, 1.59]	+
Total (95% CI)		5919		6291	100.0%	1.36 [1.15, 1.60]	•
Total events	1769		1588				
Heterogeneity: Tau <sup>2</sup> = 0.04; Chi <sup>2</sup> = 27	7.75. df = 1	1 (P = 0	.004); <b>i</b> ²:	= 60%		_	
Test for overall effect: Z = 3.64 (P = 0							0.2 0.5 1 2 5
1031101 0401011 01601. Z = 3.04 (1 = 0	.0000)						Favours [experimental] Favours [control]

### Ε

	T2DN	1	Contr	ol		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	5 Tota	Weight	: M-H, random, 95%0	CI M-H, random, 95%CI
Amira Turki 2012	429	779	261	494	10.2%	1.09 [0.87, 1.37]	
Fulan Hu 2021	123	244	113	258	6.1%	1.30 [0.92, 1.85]	
Jana V. van Vliet-Ostaptchouk 2012	2158	3680	2516	4319	16.9%	1.02 [0.93, 1.11]	+
L.J. Cui 2016	49	89	51	83	2.6%	0.77 [0.42, 1.41]	
Li Zhang 2010	36	61	34	77	2.1%	1.82 [0.92, 3.60]	
Maha S. Al-Shammari 2017	150	272	223	425	7.3%	1.11 [0.82, 1.51]	
Riyadh Saif-Ali 2011	147	270	96	216	5.9%	1.49 [1.04, 2.14]	
Vasiuddin Khan 2020	153	243	36	86	3.6%	2.36 [1.43, 3.90]	<del></del>
Wassim Y. Almawi 2013	497	821	511	924	11.8%	1.24 [1.02, 1.50]	
Xing-Ping Dai 2012	168	302	87	186	5.8%	1.43 [0.99, 2.06]	
Y. Liu 2009	886	1676	883	1825	14.7%	1.20 [1.05, 1.37]	
Yiping Li 2020	568	1077	552	1173	13.0%	1.26 [1.06, 1.48]	<b></b>
Total (95% CI)		9514		10066	100.0%	1.22 [1.10, 1.36]	◆
Total events	5364		5363				
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 24	.80, df = 1	1 (P = 0.	010); I <sup>z</sup> =	56%		_	
Test for overall effect: Z = 3.69 (P = 0.	.0002)						0.5 0.7 1 1.5 2 Favours (experimental) Favours (control)

Figure 2 The forest plot of different model. A: Allelic model; B: Recessive model; C: Dominant model; D: Co-dominant model (CC vs AA); E: Co-dominant model (AC vs AA). T2DM: Type 2 diabetes mellitus.

### DISCUSSION

Compared with previous studies, we increased the inclusion criteria of cases, excluded the interference of other factors ( *e.g.*, gestational diabetes), improved the strength of proof of the study, and made the results more reliable and stable. Our meta-analysis supported the findings of Khan *et al*[10], suggesting that the rs2237895 SNP in the *KCNQ1* gene is significantly associated with the development of T2DM in Asian populations. In the study by Cui *et al*[7], the study population had an overall overweight problem, which increased the risk of T2DM prevalence and thus confounded the findings[22].

T2DM is a multifactorial, chronic, metabolic disease[23]. The idea that genetic factors have a significant role in the development of T2DM is now more widely accepted[23], although only a few genes have been confirmed as a risk for the development of T2DM. However, many genetic characteristics associated with T2DM, such as effect sizes and risk allele frequencies, need to be explored[24]. There is a need for researchers to identify risk genetic loci for T2DM and characterize the variation at the loci, thus providing a basis for elucidating the genetic pathogenesis of T2DM.

Previous studies have shown that the *KCNQ1*, *miR-21*, and *Arg972* may be risk genes for T2DM[25,26]. *KCNQ1* gene has now been shown to be located on chromosome 11p15.5, which is approximately 400 kb in length and consists of 17 exons ranging from 47 to 1122 bp in length[27]. *KCNQ1* is associated with voltage-gated K<sup>+</sup> channels, and mutations in the *KCNQ1* gene lead to dysfunction of K<sup>+</sup> channels, which would cause diseases such as QT syndrome and familial atrial fibrillation. *KCNQ1* is expressed in many tissues[27,28], and the more studied about the *KCNQ1* gene is expressed in cardiac and pancreatic tissues[29]. Current studies suggest that the main mechanisms of T2DM development are insulin resistance and islet β-cell dysfunction[2,23]. Variants in the *KCNQ1* gene may lead to increased susceptibility to T2DM in the population by altering insulin secretion from pancreatic β-cells[30,31]. It was hypothesized that variants in the *KCNQ1* gene would lead to increased expression of *KCNQ1* protein on pancreatic β-cells, which in turn would alter the open state of voltage-gated potassium channels, decrease insulin secretion, and impair glucose storage and utilization[32].

### A

	T2DM	1	Contro	bl		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 959	%CI M-H, random, 95%CI
1.2.1 Asian							
Fulan Hu 2021	189	554	155	558	6.4%	1.35 [1.04, 1.74]	
L.J. Cui 2016	71	200	85	200	3.4%	0.74 [0.50, 1.11]	
Li Zhang 2010	114	200	77	197	3.4%	2.07 [1.38, 3.08]	
Maha S. Al-Shammari 2017	266	660	405	1032	8.3%	1.05 [0.86, 1.28]	+
Riyadh Saif-Ali 2011	207	600	124	460	6.0%	1.43 [1.09, 1.86]	
Vasiuddin Khan 2020	264	600	64	200	4.4%	1.67 [1.19, 2.34]	
Wassim Y. Almawi 2013	845	1990	815	2152	11.7%	1.21 [1.07, 1.37]	-
Xing-Ping Dai 2012	298	734	143	428	6.5%	1.36 [1.06, 1.75]	
Y. Liu 2009	1304	3770	1221	3988	13.1%	1.20 [1.09, 1.32]	•
Yiping Li 2020	802	2388	790	2584	11.9%	1.15 [1.02, 1.29]	
Subtotal (95% Cl)		11696		11799	75.1%	1.25 [1.13, 1.37]	•
Total events	4360		3879				
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 21	.78, df = 9	(P = 0.0)	10); I <sup>2</sup> = 5	9%			
Test for overall effect: Z = 4.38 (P < 0	.0001)						
1.2.2 Non-Asian							
Amira Turki 2012	643	1772	421	1148	10.2%	0.98 [0.84, 1.15]	+
Jana V. van Vliet-Ostaptchouk 2012	3896	9098	4242	10364	14.7%	1.08 [1.02, 1.14]	•
Subtotal (95% CI)		10870		11512	24.9%	1.06 [0.98, 1.14]	•
Total events	4539		4663				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.1	27, df = 1 (l	P = 0.26	); I <sup>z</sup> = 21%	6			
Test for overall effect: Z = 1.56 (P = 0	.12)						
Total (95% CI)		22566		23311	100.0%	1.19 [1.09, 1.29]	•
Total events	8899	22000	8542	20011	100.070	110[1100, 1120]	ľ
Heterogeneity: Tau <sup>2</sup> = 0.01: Chi <sup>2</sup> = 33		(P = 0		- 67%			· · · · · · · · · · · · · · · · · · ·
Test for overall effect: Z = 4.09 (P < 0		, <sub>(1</sub> . = 0.	0004),1 -	- 07 70			0.01 0.1 i 10 100
Test for subgroup differences: Chi <sup>2</sup> =	,	1 (P = 0	01) E = 9	01 7 %			Favours [experimental] Favours [control]
restior subaroup amerences: Chi*=	: 0.55. af =	1 (P = 0)	.01). <b>h</b> = 8	54.7%			

В

	T2DM	1	Contro	bl		Odds ratio	Odds ratio
tudy or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95%	6CI M-H, random, 95%CI
1.4.1 Asian							
Fulan Hu 2021	33	277	21	279	3.9%	1.66 [0.94, 2.95]	
L.J. Cui 2016	11	100	17	100	2.1%	0.60 [0.27, 1.36]	
Li Zhang 2010	39	100	20	97	3.3%	2.46 [1.30, 4.65]	<del></del>
Maha S. Al-Shammari 2017	58	320	91	516	8.0%	1.03 [0.72, 1.49]	
Riyadh Saif-Ali 2011	30	300	14	230	3.1%	1.71 [0.89, 3.31]	
Vasiuddin Khan 2020	57	300	14	100	3.3%	1.44 [0.76, 2.72]	
Wassim Y. Almawi 2013	174	995	152	1076	13.2%	1.29 [1.02, 1.63]	-
Xing-Ping Dai 2012	65	367	28	214	5.3%	1.43 [0.89, 2.31]	+
Y. Liu 2009	209	1885	169	1994	14.6%	1.35 [1.09, 1.67]	-
Yiping Li 2020	117	1194	119	1292	11.6%	1.07 [0.82, 1.40]	+
Subtotal (95% CI)		5838		5898	<b>68.5</b> %	1.29 [1.11, 1.49]	◆
Fotal events	793		645				
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12	.47, df = 9	(P = 0.19	9); <b>i²</b> = 289	%			
Test for overall effect: Z = 3.38 (P = 0.	.0007)						
1.4.2 Non-Asian							
Amira Turki 2012	107	886	80	574	9.8%	0.85 [0.62, 1.16]	
Jana V. van Vliet-Ostaptchouk 2012	869	4549	863	5182	21.7%	1.18 [1.07, 1.31]	
Subtotal (95% CI)		5435		5756	31.5%	1.04 [0.75, 1.42]	<b>•</b>
Fotal events	976		943				
Heterogeneity: Tau <sup>2</sup> = 0.04; Chi <sup>2</sup> = 3.9	93. df = 1 (F	e = 0.05)	; l² = 75%				
Test for overall effect: Z = 0.21 (P = 0.	.83)						
Total (95% CI)		11273		11654	100.0%	1.21 [1.07, 1.37]	•
Total events	1769		1588			,,	
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 18		(P = 0.0)		1%			
Test for overall effect: Z = 3.08 (P = 0.							0.01 0.1 1 10 1 Favours [experimental] Favours [control]



Jaishideng® WJD | https://www.wjgnet.com

С

	T2DM	I	Contro	bl		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95%CI	M-H, random, 95%CI
1.6.1 Asian							
Fulan Hu 2021	156	277	134	279	6.7%	1.40 [1.00, 1.95]	
L.J. Cui 2016	60	100	68	100	3.0%	0.71 [0.40, 1.26]	
Li Zhang 2010	75	100	54	97	2.8%	2.39 [1.31, 4.37]	
Maha S. Al-Shammari 2017	208	320	314	516	7.8%	1.19 [0.89, 1.60]	
Riyadh Saif-Ali 2011	177	300	110	230	6.4%	1.57 [1.11, 2.22]	—— <b>—</b> —
Vasiuddin Khan 2020	210	300	50	100	4.3%	2.33 [1.47, 3.71]	· · · · · · · · · · · · · · · · · · ·
Wassim Y. Almawi 2013	671	995	663	1076	11.5%	1.29 [1.08, 1.55]	_ <b>_</b>
Xing-Ping Dai 2012	233	367	115	214	6.5%	1.50 [1.06, 2.11]	
Y. Liu 2009	1095	1885	1052	1994	13.5%	1.24 [1.09, 1.41]	
Yiping Li 2020	685	1194	671	1292	12.3%	1.25 [1.06, 1.46]	
Subtotal (95% CI)		5838		5898	74.8%	1.35 [1.20, 1.52]	•
Total events	3570		3231				
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 17	.36, df = 9	(P = 0.0-	4); I <sup>2</sup> = 489	%			
<b>T</b> 14 <b>U U U U U U U U U U</b>	000043						
Test for overall effect: Z = 4.86 (P < 0.	.00001)						
1.6.2 Non-Asian	.00001)						
	536	886	341	574	10.2%	1.05 (0.84, 1.30)	
1.6.2 Non-Asian		886 4549	341 3379	574 5182	10.2% 15.0%	1.05 (0.84, 1.30) 1.06 (0.98, 1.15)	
1.6.2 Non-Asian Amira Turki 2012	536						
<b>1.6.2 Non-Asian</b> Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012	536	4549		5182	15.0%	1.06 [0.98, 1.15]	 •
1.6.2 Non-Asian Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012 Subtotal (95% CI)	536 3027 3563	4549 5435	3379 3720	5182	15.0%	1.06 [0.98, 1.15]	
1.6.2 Non-Asian Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012 Subtotal (95% CI) Total events	536 3027 3563 D1, df = 1 (F	4549 5435	3379 3720	5182	15.0%	1.06 [0.98, 1.15]	
<b>1.6.2 Non-Asian</b> Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.1 Test for overall effect: Z = 1.44 (P = 0	536 3027 3563 D1, df = 1 (F	4549 5435 P = 0.90)	3379 3720 ; I² = 0%	5182 5756	15.0% 25.2%	1.06 (0.98, 1.15) 1.06 (0.98, 1.15)	•
<b>1.6.2 Non-Asian</b> Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.1 Test for overall effect: Z = 1.44 (P = 0 <b>Total (95% CI)</b>	536 3027 3563 01, df = 1 (F .15)	4549 5435	3379 3720 ; I <sup>z</sup> = 0%	5182 5756	15.0%	1.06 [0.98, 1.15]	•
<b>1.6.2 Non-Asian</b> Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.1 Test for overall effect: Z = 1.44 (P = 0. <b>Total (95% CI)</b> Total events	536 3027 3563 01, df = 1 (F .15) 7133	4549 5435 P = 0.90) 11273	3379 3720 ;  *= 0% 6951	5182 5756 11654	15.0% 25.2%	1.06 (0.98, 1.15) 1.06 (0.98, 1.15)	•
<b>1.6.2 Non-Asian</b> Amira Turki 2012 Jana V. van Vliet-Ostaptchouk 2012 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.1 Test for overall effect: Z = 1.44 (P = 0 <b>Total (95% CI)</b>	536 3027 3563 01, df = 1 (F .15) 7133 .32, df = 11	4549 5435 P = 0.90) 11273	3379 3720 ;  *= 0% 6951	5182 5756 11654	15.0% 25.2%	1.06 (0.98, 1.15) 1.06 (0.98, 1.15)	0.5 0.7 1 1.5 2 Favours [experimental] Favours [control]

D

	T2DM	1	Contr	ol		Odds ratio	Odds ratio
tudy or subgroup	Events	Total	Events	Tota	l Weight	M-H, random, 95%CI	M-H, random, 95%CI
1.11.1 Asian							
Fulan Hu 2021	33	154	21	166	5.3%	1.88 [1.04, 3.42]	
L.J. Cui 2016	11	51	17	49	2.9%	0.52 [0.21, 1.26]	
Li Zhang 2010	39	64	20	63	4.0%	3.35 [1.62, 6.96]	— ·
Maha S. Al-Shammari 2017	58	180	91	293	8.7%	1.06 [0.71, 1.57]	<b>-</b>
Riyadh Saif-Ali 2011	30	153	14	134	4.4%	2.09 [1.06, 4.14]	
Vasiuddin Khan 2020	57	147	14	64	4.4%	2.26 [1.15, 4.46]	
Wassim Y. Almawi 2013	174	498	152	565	12.2%	1.46 [1.12, 1.90]	<b></b>
Xing-Ping Dai 2012	65	199	28	127	6.5%	1.72 [1.03, 2.87]	
Y. Liu 2009	209	999	169	1111	13.3%	1.47 [1.18, 1.84]	
Yiping Li 2020	117	626	119	740	11.7%	1.20 [0.91, 1.59]	+
Subtotal (95% CI)		3071		3312	73.5%	1.49 [1.22, 1.81]	•
Total events	793		645				
Heterogeneity: Tau² = 0.04; Chi² = 1: Test for overall effect: Z = 3.94 (P < 0 <b>1.11.2 Non-Asian</b>		(P = 0.0	J3), I= 5	170			
Amira Turki 2012	107	457	80	313	10.3%	0.89 [0.64, 1.24]	
		2391	863	2666	16.2%		
Jana V, van Vliet-Ostantchouk 2012						1 1911 10 1 341	
Jana V. van Vliet-Ostaptchouk 2012 Subtotal (95% CI)	000		005			1.19 [1.06, 1.34] 1.08 [0.82, 1.42]	<b>•</b>
Subtotal (95% CI)		2848		2979	26.5%	1.19 [1.08, 1.34] 1.08 [0.82, 1.42]	+
	976 .63, df = 1 (	2848	943	2979			•
<b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 2. Test for overall effect: Z = 0.53 (P = 0	976 .63, df = 1 (	2848	943	2979 %			•
<b>Subtotal (95% Cl)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 2.	976 .63, df = 1 (	2848 P = 0.10	943	2979 %	26.5%	1.08 (0.82, 1.42)	•
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 2. Test for overall effect: Z = 0.53 (P = C Total (95% CI) Total events	976 .63, df = 1 ( ).60) 1769	2848 P = 0.10 5919	943 )); I² = 62 1588	2979 % 6291	26.5%	1.08 (0.82, 1.42) 1.36 [1.15, 1.60]	• •
Subtotal (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 2. Test for overall effect: Z = 0.53 (P = C Total (95% Cl)	976 .63, df = 1 ( 0.60) 1769 7.75, df = 1	2848 P = 0.10 5919	943 )); I² = 62 1588	2979 % 6291	26.5%	1.08 (0.82, 1.42) 1.36 [1.15, 1.60]	2 0.5 1 2 urs [experimental] Favours [cont



Baisbideng® WJD | https://www.wjgnet.com

### Ε

	T2DM		Contro	bl		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95%	CI M-H, fixed, 95%CI
1.12.1 Asia							
Fulan Hu 2021	123	244	113	258	4.1%	1.30 [0.92, 1.85]	
L.J. Cui 2016	49	89	51	83	1.8%	0.77 [0.42, 1.41]	
Li Zhang 2010	36	61	34	77	0.9%	1.82 [0.92, 3.60]	
Maha S. Al-Shammari 2017	150	272	223	425	5.9%	1.11 [0.82, 1.51]	
Riyadh Saif-Ali 2011	147	270	96	216	3.7%	1.49 [1.04, 2.14]	
Vasiuddin Khan 2020	153	243	36	86	1.5%	2.36 [1.43, 3.90]	
Wassim Y. Almawi 2013	497	821	511	924	14.4%	1.24 [1.02, 1.50]	
Xing-Ping Dai 2012	168	302	87	186	3.6%	1.43 [0.99, 2.06]	
Y. Liu 2009	886	1676	883	1825	30.2%	1.20 [1.05, 1.37]	
Yiping Li 2020	568	1077	552	1173	18.9%	1.26 [1.06, 1.48]	_ <b>_</b>
Subtotal (95% CI)		5055		5253	85.0%	1.26 [1.16, 1.36]	•
Total events	2777		2586				
Heterogeneity: $Chi^2 = 12.27$ , df = 9 (f Test for overall effect: Z = 5.74 (P < 0	71	²= 27%					
1.12.2 Non-Asian							
Amira Turki 2012	429	779	261	494	10.9%	1.09 [0.87, 1.37]	- <b>+</b> •
Jana V. van Vliet-Ostaptchouk 2012	123	244	113	258	4.1%	1.30 [0.92, 1.85]	
Subtotal (95% CI)		1023		752	15.0%	1.15 [0.95, 1.39]	
Total events	552		374				
Heterogeneity: Chi² = 0.68, df = 1 (P Test for overall effect: Z = 1.46 (P = 0		= 0%					
Total (95% CI)		6078		6005	100.0%	1.24 [1.15, 1.33]	◆
Total events	3329		2960				
Heterogeneity: Chi <sup>2</sup> = 13.64, df = 11 Test for overall effect: Z = 5.87 (P < 0 Test for subgroup differences: Chi <sup>2</sup> :	(P = 0.25); 1.00001)		%	0%		-	0.5 0.7 1 1.5 2 Favours [experimental] Favours [control]

Figure 3 The forest plot for stratified analysis of different model. A: Allelic model; B: Recessive model; C: Dominant model; D: Co-dominant model (CC vs AA); E: Co-dominant model (AC vs AA). T2DM: Type 2 diabetes mellitus.




Figure 4 The funnel plot of different model. A: Allelic model; B: Recessive model; C: Dominant model; D: Co-dominant model (CC vs AA); E: Co-dominant model (AC vs AA). OR: Odds ratio.




Figure 5 The funnel plot for stratified analysis of different models. A: Allelic model; B: Recessive model; C: Dominant model; D: Co-dominant model (CC vs AA); E: Co-dominant model (AC vs AA). OR: Odds ratio.

This meta-analysis of the *KCNQ1* gene rs2237895 SNP and T2DM association study involved 12 studies, including 11273 T2DM patients and 11654 controls. This analysis showed that the rs2237895 polymorphism was significantly associated with an elevated risk of developing T2DM in an Asian population, which is consistent with Khan *et al*'s[10] findings. In Asian populations, C allele carriers have an increased risk of developing T2DM. The risk of T2DM is also increased in people with the CC and AC genotypes compared to the AA genotype. This is consistent with the previous findings of Hu *et al*[16]. Also, their findings showed that rs2237895 was associated with hypertension, body mass index, and hypertriglyceridemia. In non-Asian populations, this association was not significant. A 2015 study by Rios *et al*[33] in Europeans also showed that the *KCNQ1* gene rs2237895 SNP was not significantly associated with T2DM, which is consistent with our findings. Our work provided strong evidence for the genetic pathogenesis of T2DM and helped to fully reveal the pathogenesis of T2DM.

This study showed that the rs2237895 SNP of the *KCNQ1* gene was differentially associated with T2DM in different populations. The reasons for this variation may be mutations in the regulatory region of the *KCNQ1* gene in particular populations[33], which interfere with the expression of the *KCNQ1* gene; or it may be due to the existence of different genotypes and allele frequencies in populations with different clinical characteristics, geographical distribution and ethnic origin; or differences in the external influences associated with T2DM, such as lifestyle and behavior, in different populations[4,23-25]. The possibility of false-negative results in non-Asian populations with small study sample sizes cannot be excluded.

### CONCLUSION

In the Asian population, there was a significant association between the *KCNQ1* gene rs2237895 SNP and T2DM onset. C allele carriers were at increased risk of T2DM, and the CC and AC genotypes significantly increased the susceptibility to T2DM. However, in the non-Asian population, the association between rs2237895 and T2DM onset was not significant.

### **ARTICLE HIGHLIGHTS**

### Research background

The association between the rs2237895 single nucleotide polymorphism (SNP) in the *KCNQ1* gene and the prevalence of type 2 diabetes mellitus (T2DM) has been controversial in different studies.

WJD https://www.wjgnet.com

### Research motivation

The aim of this study was to investigate the association between the KCNQ1 gene rs2237895 and the prevalence of T2DM, and to provide help in establishing the pathogenesis of T2DM.

### Research objectives

Demonstration of the association of the rs2237895 SNP in the KCNQ1 gene with the prevalence of T2DM. Also, to explore whether this relationship differs in different populations.

### Research methods

We searched nine databases. Two authors independently screened the literature according to the established inclusion and exclusion criteria. Finally, data extraction was performed and the data were meta-analyzed.

### **Research results**

Twelve case-control studies met our inclusion criteria. After analysis, the rs2237895 SNP in the KCNQ1 gene was associated with T2DM prevalence in Asian populations. However, this association was not significant in non-Asian populations.

### Research conclusions

In Asian populations, carriers of the rs2237895 C allele of the KCNQ1 gene were highly susceptible to T2DM compared to those who did not carry the C allele. However, in non-Asian populations, the association between the rs2237895 SNP and T2DM was not significant.

### Research perspectives

We should continue to search for T2DM susceptibility genes through advanced technologies (e.g., genome-wide association strategy) and gradually elucidate the pathogenesis of T2DM.

### FOOTNOTES

Co-first authors: Dong-Xu Li and Li-Ping Yin.

Co-corresponding authors: Chen-Sen He and Jiang-Jie Sun.

Author contributions: Li DX, Yin LP, Sun JJ, and He CS designed this study (substantial contributions to the conception); Li DX, Yin LP, Song YQ, Shao NN, and Zhu H collected data; Li DX and Yin LP extracted and analyzed data, interpretation of data for the work; Sun JJ and He CS provided guidance for statistical analysis and provided financial support. They agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy; Li DX and Yin LP wrote the manuscript; Li DX, Yin LP, Song YQ, Shao NN, Zhu H, Sun JJ and He CS reviewed the manuscript; Li DX and Yin LP contributed equally to this work as co-first authors; Sun JJ and He CS contributed equally to this work as co-corresponding authors. The reasons for designating Li DX and Yin LP as co-first authors are as follows. First, Li DX and Yin LP contributed equal effort throughout the study. The selection of these researchers as co-first authors respects their equal contributions. Second, the research was conducted as a collaborative effort, and the designation of co-first authors accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the research and final paper. The reasons for designating Sun JJ and He CS as co-corresponding authors are as follows. First, Sun JJ and He CS put equal effort into the entire study. Second, the designation of co-corresponding authors best reflects the need for this study to have authors from different fields, which promotes the most in-depth examination of the research topic. In summary, we believe that the designation of Li DX and Yin LP as co-first authors and Sun JJ and He CS as co-corresponding authors meets the requirements of our manuscript, which reflects the spirit of equality and cooperation in our team.

Supported by the Natural Science Foundation for the Higher Education Institutions of Anhui Province of China, No. 2023AH050561, No. 2022AH051143, No. KJ2021A0266, and No. KJ2021A1228; and School-level offline courses, No. 2021xjkc13.

Conflict-of-interest statement: The authors declare no competing interests.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

### Country/Territory of origin: China

ORCID number: Jiang-Jie Sun 0000-0002-8185-0802.

S-Editor: Lin C L-Editor: A



### REFERENCES

- IDF Diabetes Atlas [Internet]. Brussels: International Diabetes Federation; 2021 [PMID: 35914061] 1
- 2 García-Chapa EG, Leal-Ugarte E, Peralta-Leal V, Durán-González J, Meza-Espinoza JP. Genetic Epidemiology of Type 2 Diabetes in Mexican Mestizos. Biomed Res Int 2017; 2017: 3937893 [PMID: 28607931 DOI: 10.1155/2017/3937893]
- Xu J, Zhang W, Song W, Cui J, Tian Y, Chen H, Huang P, Yang S, Wang L, He X, Shi B, Cui W. Relationship Between KCNQ1 3 Polymorphism and Type 2 Diabetes Risk in Northwestern China. Pharmgenomics Pers Med 2021; 14: 1731-1751 [PMID: 35002291 DOI: 10.2147/PGPM.S340813]
- Nawata H, Shirasawa S, Nakashima N, Araki E, Hashiguchi J, Miyake S, Yamauchi T, Hamaguchi K, Yoshimatsu H, Takeda H, Fukushima 4 H, Sasahara T, Yamaguchi K, Sonoda N, Sonoda T, Matsumoto M, Tanaka Y, Sugimoto H, Tsubouchi H, Inoguchi T, Yanase T, Wake N, Narazaki K, Eto T, Umeda F, Nakazaki M, Ono J, Asano T, Ito Y, Akazawa S, Hazegawa I, Takasu N, Shinohara M, Nishikawa T, Nagafuchi S, Okeda T, Eguchi K, Iwase M, Ishikawa M, Aoki M, Keicho N, Kato N, Yasuda K, Yamamoto K, Sasazuki T. Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13-p12 in Japanese. J Hum Genet 2004; 49: 629-634 [PMID: 15490285 DOI: 10.1007/s10038-004-0199-3]
- Xu N, Zhang TT, Han WJ, Yin LP, Ma NZ, Shi XY, Sun JJ. Association of CDKAL1 RS10946398 Gene Polymorphism with Susceptibility to 5 Diabetes Mellitus Type 2: A Meta-Analysis. J Diabetes Res 2021; 2021: 1254968 [PMID: 34977253 DOI: 10.1155/2021/1254968]
- 6 Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, Edlund A, Pedersen MG, Jonsson A, Ramracheya R, Tang Y, Walker JN, Barrett A, Johnson PR, Lyssenko V, McCarthy MI, Groop L, Salehi A, Gloyn AL, Renström E, Rorsman P, Eliasson L. Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes. Diabetes 2012; 61: 1726-1733 [PMID: 22492527 DOI: 10.2337/db11-1516]
- Cui LJ, Chang XY, Zhu LY, Feng G, Zhou T, Zhang CX, Chong KY, Sun K. Relationship between the polymorphisms in KCNQ1 and type 2 7 diabetes in Chinese Kazakh population. Genet Mol Res 2016; 15 [PMID: 27323013 DOI: 10.4238/gmr.15027503]
- Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, Ng DP, Holmkvist J, Borch-Johnsen K, Jørgensen T, Sandbaek A, 8 Lauritzen T, Hansen T, Nurbaya S, Tsunoda T, Kubo M, Babazono T, Hirose H, Hayashi M, Iwamoto Y, Kashiwagi A, Kaku K, Kawamori R, Tai ES, Pedersen O, Kamatani N, Kadowaki T, Kikkawa R, Nakamura Y, Maeda S. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40: 1098-1102 [PMID: 18711366 DOI: 10.1038/ng.208]
- Afshardoost S, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. The influence of a genetic variant in the KCNQ1 gene on type 2 9 diabetes mellitus development. Gene Rep 2019; 17: 100529 [DOI: 10.1016/j.genrep.2019.100529]
- Khan V, Verma AK, Bhatt D, Khan S, Hasan R, Goyal Y, Ramachandran S, Alsahli MA, Rahmani AH, Almatroudi A, Shareef MY, Meena B, 10 Dev K. Association of Genetic Variants of KCNJ11 and KCNQ1 Genes with Risk of Type 2 Diabetes Mellitus (T2DM) in the Indian Population: A Case-Control Study. Int J Endocrinol 2020; 2020: 5924756 [PMID: 33101408 DOI: 10.1155/2020/5924756]
- Sun Q, Song K, Shen X, Cai Y. The association between KCNQ1 gene polymorphism and type 2 diabetes risk: a meta-analysis. PLoS One 11 2012; 7: e48578 [PMID: 23133642 DOI: 10.1371/journal.pone.0048578]
- 12 Liu Y, Zhou DZ, Zhang D, Chen Z, Zhao T, Zhang Z, Ning M, Hu X, Yang YF, Zhang ZF, Yu L, He L, Xu H. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes in the population of mainland China. Diabetologia 2009; 52: 1315-1321 [PMID: 19448982 DOI: 10.1007/s00125-009-1375-y]
- Zhang L. The relationship of polymorphisms of rs2237895 in KCNQ1 gene with type 2 diabetes in Han population of Bengbu distric. 13 M.Med. Thesis, BengBu Medical College. 2010. Available from: https://d.wanfangdata.com.cn/thesis/ ChJUaGVzaXNOZXdTMjAyMzA5MDESB0Q2NjcxNTcaCGN5cnp4Y3I0
- Dai XP, Huang Q, Yin JY, Guo Y, Gong ZC, Lei MX, Jiang TJ, Zhou HH, Liu ZQ. KCNQ1 gene polymorphisms are associated with the 14 therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol 2012; 39: 462-468 [PMID: 22414228 DOI: 10.1111/j.1440-1681.2012.05701.x]
- Li Y, Shen K, Li C, Yang Y, Yang M, Tao W, He S, Shi L, Yao Y. Identifying the association between single nucleotide polymorphisms in 15 KCNQ1, ARAP1, and KCNJ11 and type 2 diabetes mellitus in a Chinese population. Int J Med Sci 2020; 17: 2379-2386 [PMID: 32922204 DOI: 10.7150/ijms.48072]
- Hu F, Zhang Y, Qin P, Zhao Y, Liu D, Zhou Q, Tian G, Li Q, Guo C, Wu X, Qie R, Huang S, Han M, Li Y, Zhang M, Hu D. Integrated 16 analysis of probability of type 2 diabetes mellitus with polymorphisms and methylation of KCNQ1 gene: A nested case-control study. J Diabetes 2021; 13: 975-986 [PMID: 34260825 DOI: 10.1111/1753-0407.13212]
- Saif-Ali R, Ismail IS, Al-Hamodi Z, Al-Mekhlafi HM, Siang LC, Alabsi AM, Muniandy S. KCNQ1 haplotypes associate with type 2 diabetes 17 in Malaysian Chinese Subjects. Int J Mol Sci 2011; 12: 5705-5718 [PMID: 22016621 DOI: 10.3390/ijms12095705]
- Almawi WY, Nemr R, Keleshian SH, Echtay A, Saldanha FL, AlDoseri FA, Racoubian E. A replication study of 19 GWAS-validated type 2 18 diabetes at-risk variants in the Lebanese population. Diabetes Res Clin Pract 2013; 102: 117-122 [PMID: 24145053 DOI: 10.1016/j.diabres.2013.09.001]
- 19 Al-Shammari MS, Al-Ali R, Al-Balawi N, Al-Enazi MS, Al-Muraikhi AA, Busaleh FN, Al-Sahwan AS, Al-Elq A, Al-Nafaie AN, Borgio JF, AbdulAzeez S, Al-Ali A, Acharya S. Type 2 diabetes associated variants of KCNQ1 strongly confer the risk of cardiovascular disease among the Saudi Arabian population. Genet Mol Biol 2017; 40: 586-590 [PMID: 28863213 DOI: 10.1590/1678-4685-GMB-2017-0005]
- van Vliet-Ostaptchouk JV, van Haeften TW, Landman GW, Reiling E, Kleefstra N, Bilo HJ, Klungel OH, de Boer A, van Diemen CC, 20 Wijmenga C, Boezen HM, Dekker JM, van 't Riet E, Nijpels G, Welschen LM, Zavrelova H, Bruin EJ, Elbers CC, Bauer F, Onland-Moret NC, van der Schouw YT, Grobbee DE, Spijkerman AM, van der A DL, Simonis-Bik AM, Eekhoff EM, Diamant M, Kramer MH, Boomsma DI, de Geus EJ, Willemsen G, Slagboom PE, Hofker MH, 't Hart LM. Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. PLoS One 2012; 7: e32148 [PMID: 22403629 DOI: 10.1371/journal.pone.0032148]
- Turki A, Mtiraoui N, Al-Busaidi AS, Khirallah M, Mahjoub T, Almawi WY. Lack of association between genetic polymorphisms within 21 KCNQ1 locus and type 2 diabetes in Tunisian Arabs. Diabetes Res Clin Pract 2012; 98: 452-458 [PMID: 23107108 DOI:



### Li DX et al. KCNQ1 rs2237895 polymorphism increases T2DM risk

10.1016/j.diabres.2012.10.006

- 22 Naude CE, Brand A, Schoonees A, Nguyen KA, Chaplin M, Volmink J. Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk. Cochrane Database Syst Rev 2022; 1: CD013334 [PMID: 35088407 DOI: 10.1002/14651858.CD013334.pub2]
- Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346 [PMID: 23 15823385 DOI: 10.1016/S0140-6736(05)61032-X]
- Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko 24 I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, Lindgren CM, Müller-Nurasyid M, Pechlivanis S, Rayner NW, Scott LJ, Wiltshire S, Yengo L, Kinnunen L, Rossin EJ, Raychaudhuri S, Johnson AD, Dimas AS, Loos RJ, Vedantam S, Chen H, Florez JC, Fox C, Liu CT, Rybin D, Couper DJ, Kao WH, Li M, Cornelis MC, Kraft P, Sun Q, van Dam RM, Stringham HM, Chines PS, Fischer K, Fontanillas P, Holmen OL, Hunt SE, Jackson AU, Kong A, Lawrence R, Meyer J, Perry JR, Platou CG, Potter S, Rehnberg E, Robertson N, Sivapalaratnam S, Stančáková A, Stirrups K, Thorleifsson G, Tikkanen E, Wood AR, Almgren P, Atalay M, Benediktsson R, Bonnycastle LL, Burtt N, Carey J, Charpentier G, Crenshaw AT, Doney AS, Dorkhan M, Edkins S, Emilsson V, Eury E, Forsen T, Gertow K, Gigante B, Grant GB, Groves CJ, Guiducci C, Herder C, Hreidarsson AB, Hui J, James A, Jonsson A, Rathmann W, Klopp N, Kravic J, Krjutškov K, Langford C, Leander K, Lindholm E, Lobbens S, Männistö S, Mirza G, Mühleisen TW, Musk B, Parkin M, Rallidis L, Saramies J, Sennblad B, Shah S, Sigurðsson G, Silveira A, Steinbach G, Thorand B, Trakalo J, Veglia F, Wennauer R, Winckler W, Zabaneh D, Campbell H, van Duijn C, Uitterlinden AG, Hofman A, Sijbrands E, Abecasis GR, Owen KR, Zeggini E, Trip MD, Forouhi NG, Syvänen AC, Eriksson JG, Peltonen L, Nöthen MM, Balkau B, Palmer CN, Lyssenko V, Tuomi T, Isomaa B, Hunter DJ, Qi L; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium, Shuldiner AR, Roden M, Barroso I, Wilsgaard T, Beilby J, Hovingh K, Price JF, Wilson JF, Rauramaa R, Lakka TA, Lind L, Dedoussis G, Njølstad I, Pedersen NL, Khaw KT, Wareham NJ, Keinanen-Kiukaanniemi SM, Saaristo TE, Korpi-Hyövälti E, Saltevo J, Laakso M, Kuusisto J, Metspalu A, Collins FS, Mohlke KL, Bergman RN, Tuomilehto J, Boehm BO, Gieger C, Hveem K, Cauchi S, Froguel P, Baldassarre D, Tremoli E, Humphries SE, Saleheen D, Danesh J, Ingelsson E, Ripatti S, Salomaa V, Erbel R, Jöckel KH, Moebus S, Peters A, Illig T, de Faire U, Hamsten A, Morris AD, Donnelly PJ, Frayling TM, Hattersley AT, Boerwinkle E, Melander O, Kathiresan S, Nilsson PM, Deloukas P, Thorsteinsdottir U, Groop LC, Stefansson K, Hu F, Pankow JS, Dupuis J, Meigs JB, Altshuler D, Boehnke M, McCarthy MI; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-990 [PMID: 22885922] DOI: 10.1038/ng.2383]
- 25 Li Y, Yang J, Tao W, Yang M, Wang X, Lu T, Li C, Yang Y, Yao Y. The Single Nucleotide Polymorphisms (rs1292037 and rs13137) in miR-21 Were Associated with T2DM in a Chinese Population. Diabetes Metab Syndr Obes 2022; 15: 189-198 [PMID: 35087281 DOI: 10.2147/DMSO.S345758]
- Mannino GC, Andreozzi F, Sesti G. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes Metab Res 26 *Rev* 2019; **35**: e3109 [PMID: 30515958 DOI: 10.1002/dmrr.3109]
- Han WJ, Deng JY, Jin H, Yin LP, Yang JX, Sun JJ. Association of KCNQ1rs2237892C. T Gene with Type 2 Diabetes Mellitus: A Meta-27 Analysis. J Diabetes Res 2021; 2021: 6606830 [PMID: 34853793 DOI: 10.1155/2021/6606830]
- 28 Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Fauré S, Gary F, Coumel P, Petit C, Schwartz K, Guicheney P. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 1997; 15: 186-189 [PMID: 9020846 DOI: 10.1038/ng0297-186]
- 29 Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, Jin HW, Sun H, Su XY, Zhuang QN, Yang YQ, Li YB, Liu Y, Xu HJ, Li XF, Ma N, Mou CP, Chen Z, Barhanin J, Huang W. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299: 251-254 [PMID: 12522251 DOI: 10.1126/science.1077771]
- Ullrich S, Su J, Ranta F, Wittekindt OH, Ris F, Rösler M, Gerlach U, Heitzmann D, Warth R, Lang F. Effects of I(Ks) channel inhibitors in 30 insulin-secreting INS-1 cells. *Pflugers Arch* 2005; **451**: 428-436 [PMID: 16133261 DOI: 10.1007/s00424-005-1479-2]
- Jonsson A, Isomaa B, Tuomi T, Taneera J, Salehi A, Nilsson P, Groop L, Lyssenko V. A variant in the KCNQ1 gene predicts future type 2 31 diabetes and mediates impaired insulin secretion. Diabetes 2009; 58: 2409-2413 [PMID: 19584308 DOI: 10.2337/db09-0246]
- Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, 32 Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753 [PMID: 19812666 DOI: 10.1038/nature08494]
- Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, 33 Cayuela AJ, Wetek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer 2015; 22: 545-559 [PMID: 26099684 DOI: 10.1530/ERC-15-0029]



WJD | https://www.wjgnet.com



# Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

